Holen Sie sich die Stockscreener-App
61.15
0.50%
-0.31
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$61.46
Offen:
$60.66
24-Stunden-Volumen:
9.64M
Relative Volume:
0.89
Marktkapitalisierung:
$124.91B
Einnahmen:
$48.48B
Nettoeinkommen (Verlust:
$7.27B
KGV:
17.16
EPS:
3.5626
Netto-Cashflow:
$11.91B
1W Leistung:
-2.72%
1M Leistung:
-9.62%
6M Leistung:
+2.60%
1J Leistung:
+33.72%
1-Tages-Spanne:
$60.24
$61.24
1-Wochen-Bereich:
$60.24
$64.13
52-Wochen-Spanne:
$42.52
$68.64
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
61.15 | 128.41B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,142.85 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.03 | 623.34B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
262.82 | 459.33B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
144.30 | 354.80B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.00 | 268.10B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-12-12 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale - currently.att.yahoo.com
Autoimmune CAR T Safety Events Reshape Rheumatologist Sentiment, but Autologous CAR T Retains Lead, According to Spherix Global Insights - GlobeNewswire Inc.
United Therapeutics’ legal victory; BMS’ Camzyos approved for kids - Endpoints News
Bristol Myers Squibb (BMY) Boosts Champions in Care Initiative w - GuruFocus
Healthcare professionals can nominate nonprofits for Bristol Myers Squibb's $1 million grants - Stock Titan
Children with this heart condition have one FDA-approved option: Bristol Myers Squibb's CAMZYOS. - Stock Titan
FDA Approves Bristol Myers Squibb's Camzyos for Pediatric Obstru - GuruFocus
Jamaal Sebastian-Barnes Elevated to Senior Vice President, Head of HR – Research and Development at Bristol Myers Squibb - hrtoday.in
FDA Approves Bristol Myers' Camzyos for Pediatric Obstructive Hy - GuruFocus
Portal Innovations CEO John Flavin expects more pharma acquisitions of Houston companies - The Business Journals
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - GlobeNewswire Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast - GlobeNewswire Inc.
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Bristol Myers Squibb (BMY) Faces Liver Injury Concerns in Admilp - GuruFocus
Why Are ZENBEXUS Data Putting Bristol-Myers (NYSE:BMY) in Focus? - Kalkine Media
3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation - The Motley Fool
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Bristol Myers Squibb awarded honour for being first employer to gain triple-region Menopause Friendly Accreditation - hrnews.co.uk
Bristol-Myers Squibb Co (BRM.HM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover? - Insider Monkey
Bristol Myers Squibb posts first Phase 3 results for ZENBEXUS combo in multiple myeloma - app.dealroom.co
Bristol Myers Squibb’s Zenbexus shows improved response rates - Investing.com
Bristol Myers Squibb’s Zenbexus shows improved response rates By Investing.com - Investing.com Canada
Bristol Myers Squibb (NYSE:BMY) Upgraded to Strong-Buy at Zacks Research - MarketBeat
Zacks Research Brokers Increase Earnings Estimates for BMY - MarketBeat
Bristol Myers Squibb Company (NYSE:BMY) Stock Has Consensus Target Price of $67.06 - MarketBeat
Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY? - TradingView
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now? - The Motley Fool
Bristol Myers Squibb announces 265 additional job cuts - medwatch.com
Engineers Gate Manager LP Decreases Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb To Cut 265 More Jobs Tied To Its New Jersey Operations - communitynews.org
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Goldman Sachs reiterates Bristol-Myers Squibb stock Neutral rating - Investing.com
Goldman Sachs reiterates Bristol-Myers Squibb stock Neutral rating By Investing.com - Investing.com Canada
How AI Is Accelerating Drug Discovery And Patient Health At Bristol Myers Squibb - Forbes
Layoff Tracker: Novo workforce down 13,000 - BioSpace
Bristol Myers Squibb stock slips at the close - AD HOC NEWS
Bristol Myers cuts another 265 jobs tied to New Jersey headquarters - Fierce Pharma
State Street Corp Has $6.09 Billion Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Pharmaceutical giant to lay off 265 N.J. workers in 3rd wave of job cuts this year - NJ.com
Bristol Myers Squibb invests $2.3B in Houston campus - scanx.trade
Bristol Myers Squibb stock gains support as 2026 outlook and consensus improve - ad-hoc-news.de
Bristol-Myers Squibb (BMY) Stock Analysis: A Healthcare Giant With 5.79% Upside Potential - DirectorsTalk Interviews
Bristol Myers Squibb stock heads into the open after a 0.8 percent gain - AD HOC NEWS
Bristol-Myers Squibb stock heads into the open after a 0.8% gain - AD HOC NEWS
Bristol-Myers Squibb (NYSE:BMY): Its history spans 16 decades, but the next few years could be the most important ever! - Stocks Down Under
Bristol Myers Squibb stops work on Orum's ORM-6151 after Phase 1 data - app.dealroom.co
Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder - The Motley Fool
Bristol Myers Squibb stock holds near USD 63 as investors look to October 29 results - AD HOC NEWS
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):